Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Rotator Cuff Arthropathy Repair Market

ID: MRFR/HC/10892-HCR
132 Pages
Vikita Thakur
Last Updated: April 06, 2026

Rotator Cuff Arthropathy Repair Market Research Report Information By Treatment Type (Reverse Total Shoulder Replacement, Muscle/Tendon Transfer, Partial Joint Replacement and Others), By Age Group (Less than 50, From 50 to 65 and From 65 to 70) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World), Forecast Till 2035.

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Rotator Cuff Arthropathy Repair Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Treatment Type (USD Billion)
  49.     4.1.1 Reverse Total Shoulder Replacement
  50.     4.1.2 Muscle/Tendon Transfer
  51.     4.1.3 Partial Joint Replacement
  52.     4.1.4 Others
  53.   4.2 Healthcare, BY Age Group (USD Billion)
  54.     4.2.1 Less than 50
  55.     4.2.2 From 50 to 65
  56.     4.2.3 From 65 to 70
  57.   4.3 Healthcare, BY Region (USD Billion)
  58.     4.3.1 North America
  59.       4.3.1.1 US
  60.       4.3.1.2 Canada
  61.     4.3.2 Europe
  62.       4.3.2.1 Germany
  63.       4.3.2.2 UK
  64.       4.3.2.3 France
  65.       4.3.2.4 Russia
  66.       4.3.2.5 Italy
  67.       4.3.2.6 Spain
  68.       4.3.2.7 Rest of Europe
  69.     4.3.3 APAC
  70.       4.3.3.1 China
  71.       4.3.3.2 India
  72.       4.3.3.3 Japan
  73.       4.3.3.4 South Korea
  74.       4.3.3.5 Malaysia
  75.       4.3.3.6 Thailand
  76.       4.3.3.7 Indonesia
  77.       4.3.3.8 Rest of APAC
  78.     4.3.4 South America
  79.       4.3.4.1 Brazil
  80.       4.3.4.2 Mexico
  81.       4.3.4.3 Argentina
  82.       4.3.4.4 Rest of South America
  83.     4.3.5 MEA
  84.       4.3.5.1 GCC Countries
  85.       4.3.5.2 South Africa
  86.       4.3.5.3 Rest of MEA
  87. 5 SECTION V: COMPETITIVE ANALYSIS
  88.   5.1 Competitive Landscape
  89.     5.1.1 Overview
  90.     5.1.2 Competitive Analysis
  91.     5.1.3 Market share Analysis
  92.     5.1.4 Major Growth Strategy in the Healthcare
  93.     5.1.5 Competitive Benchmarking
  94.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  95.     5.1.7 Key developments and growth strategies
  96.       5.1.7.1 New Product Launch/Service Deployment
  97.       5.1.7.2 Merger & Acquisitions
  98.       5.1.7.3 Joint Ventures
  99.     5.1.8 Major Players Financial Matrix
  100.       5.1.8.1 Sales and Operating Income
  101.       5.1.8.2 Major Players R&D Expenditure. 2023
  102.   5.2 Company Profiles
  103.     5.2.1 Smith & Nephew (GB)
  104.       5.2.1.1 Financial Overview
  105.       5.2.1.2 Products Offered
  106.       5.2.1.3 Key Developments
  107.       5.2.1.4 SWOT Analysis
  108.       5.2.1.5 Key Strategies
  109.     5.2.2 Stryker (US)
  110.       5.2.2.1 Financial Overview
  111.       5.2.2.2 Products Offered
  112.       5.2.2.3 Key Developments
  113.       5.2.2.4 SWOT Analysis
  114.       5.2.2.5 Key Strategies
  115.     5.2.3 DePuy Synthes (US)
  116.       5.2.3.1 Financial Overview
  117.       5.2.3.2 Products Offered
  118.       5.2.3.3 Key Developments
  119.       5.2.3.4 SWOT Analysis
  120.       5.2.3.5 Key Strategies
  121.     5.2.4 Arthrex (US)
  122.       5.2.4.1 Financial Overview
  123.       5.2.4.2 Products Offered
  124.       5.2.4.3 Key Developments
  125.       5.2.4.4 SWOT Analysis
  126.       5.2.4.5 Key Strategies
  127.     5.2.5 Zimmer Biomet (US)
  128.       5.2.5.1 Financial Overview
  129.       5.2.5.2 Products Offered
  130.       5.2.5.3 Key Developments
  131.       5.2.5.4 SWOT Analysis
  132.       5.2.5.5 Key Strategies
  133.     5.2.6 Medtronic (US)
  134.       5.2.6.1 Financial Overview
  135.       5.2.6.2 Products Offered
  136.       5.2.6.3 Key Developments
  137.       5.2.6.4 SWOT Analysis
  138.       5.2.6.5 Key Strategies
  139.     5.2.7 Conmed (US)
  140.       5.2.7.1 Financial Overview
  141.       5.2.7.2 Products Offered
  142.       5.2.7.3 Key Developments
  143.       5.2.7.4 SWOT Analysis
  144.       5.2.7.5 Key Strategies
  145.     5.2.8 Aesculap (DE)
  146.       5.2.8.1 Financial Overview
  147.       5.2.8.2 Products Offered
  148.       5.2.8.3 Key Developments
  149.       5.2.8.4 SWOT Analysis
  150.       5.2.8.5 Key Strategies
  151.   5.3 Appendix
  152.     5.3.1 References
  153.     5.3.2 Related Reports
  154. 6 LIST OF FIGURES
  155.   6.1 MARKET SYNOPSIS
  156.   6.2 NORTH AMERICA MARKET ANALYSIS
  157.   6.3 US MARKET ANALYSIS BY TREATMENT TYPE
  158.   6.4 US MARKET ANALYSIS BY AGE GROUP
  159.   6.5 CANADA MARKET ANALYSIS BY TREATMENT TYPE
  160.   6.6 CANADA MARKET ANALYSIS BY AGE GROUP
  161.   6.7 EUROPE MARKET ANALYSIS
  162.   6.8 GERMANY MARKET ANALYSIS BY TREATMENT TYPE
  163.   6.9 GERMANY MARKET ANALYSIS BY AGE GROUP
  164.   6.10 UK MARKET ANALYSIS BY TREATMENT TYPE
  165.   6.11 UK MARKET ANALYSIS BY AGE GROUP
  166.   6.12 FRANCE MARKET ANALYSIS BY TREATMENT TYPE
  167.   6.13 FRANCE MARKET ANALYSIS BY AGE GROUP
  168.   6.14 RUSSIA MARKET ANALYSIS BY TREATMENT TYPE
  169.   6.15 RUSSIA MARKET ANALYSIS BY AGE GROUP
  170.   6.16 ITALY MARKET ANALYSIS BY TREATMENT TYPE
  171.   6.17 ITALY MARKET ANALYSIS BY AGE GROUP
  172.   6.18 SPAIN MARKET ANALYSIS BY TREATMENT TYPE
  173.   6.19 SPAIN MARKET ANALYSIS BY AGE GROUP
  174.   6.20 REST OF EUROPE MARKET ANALYSIS BY TREATMENT TYPE
  175.   6.21 REST OF EUROPE MARKET ANALYSIS BY AGE GROUP
  176.   6.22 APAC MARKET ANALYSIS
  177.   6.23 CHINA MARKET ANALYSIS BY TREATMENT TYPE
  178.   6.24 CHINA MARKET ANALYSIS BY AGE GROUP
  179.   6.25 INDIA MARKET ANALYSIS BY TREATMENT TYPE
  180.   6.26 INDIA MARKET ANALYSIS BY AGE GROUP
  181.   6.27 JAPAN MARKET ANALYSIS BY TREATMENT TYPE
  182.   6.28 JAPAN MARKET ANALYSIS BY AGE GROUP
  183.   6.29 SOUTH KOREA MARKET ANALYSIS BY TREATMENT TYPE
  184.   6.30 SOUTH KOREA MARKET ANALYSIS BY AGE GROUP
  185.   6.31 MALAYSIA MARKET ANALYSIS BY TREATMENT TYPE
  186.   6.32 MALAYSIA MARKET ANALYSIS BY AGE GROUP
  187.   6.33 THAILAND MARKET ANALYSIS BY TREATMENT TYPE
  188.   6.34 THAILAND MARKET ANALYSIS BY AGE GROUP
  189.   6.35 INDONESIA MARKET ANALYSIS BY TREATMENT TYPE
  190.   6.36 INDONESIA MARKET ANALYSIS BY AGE GROUP
  191.   6.37 REST OF APAC MARKET ANALYSIS BY TREATMENT TYPE
  192.   6.38 REST OF APAC MARKET ANALYSIS BY AGE GROUP
  193.   6.39 SOUTH AMERICA MARKET ANALYSIS
  194.   6.40 BRAZIL MARKET ANALYSIS BY TREATMENT TYPE
  195.   6.41 BRAZIL MARKET ANALYSIS BY AGE GROUP
  196.   6.42 MEXICO MARKET ANALYSIS BY TREATMENT TYPE
  197.   6.43 MEXICO MARKET ANALYSIS BY AGE GROUP
  198.   6.44 ARGENTINA MARKET ANALYSIS BY TREATMENT TYPE
  199.   6.45 ARGENTINA MARKET ANALYSIS BY AGE GROUP
  200.   6.46 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT TYPE
  201.   6.47 REST OF SOUTH AMERICA MARKET ANALYSIS BY AGE GROUP
  202.   6.48 MEA MARKET ANALYSIS
  203.   6.49 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT TYPE
  204.   6.50 GCC COUNTRIES MARKET ANALYSIS BY AGE GROUP
  205.   6.51 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT TYPE
  206.   6.52 SOUTH AFRICA MARKET ANALYSIS BY AGE GROUP
  207.   6.53 REST OF MEA MARKET ANALYSIS BY TREATMENT TYPE
  208.   6.54 REST OF MEA MARKET ANALYSIS BY AGE GROUP
  209.   6.55 KEY BUYING CRITERIA OF HEALTHCARE
  210.   6.56 RESEARCH PROCESS OF MRFR
  211.   6.57 DRO ANALYSIS OF HEALTHCARE
  212.   6.58 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  213.   6.59 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  214.   6.60 SUPPLY / VALUE CHAIN: HEALTHCARE
  215.   6.61 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
  216.   6.62 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Billion)
  217.   6.63 HEALTHCARE, BY AGE GROUP, 2024 (% SHARE)
  218.   6.64 HEALTHCARE, BY AGE GROUP, 2024 TO 2035 (USD Billion)
  219.   6.65 BENCHMARKING OF MAJOR COMPETITORS
  220. 7 LIST OF TABLES
  221.   7.1 LIST OF ASSUMPTIONS
  222.     7.1.1
  223.   7.2 North America MARKET SIZE ESTIMATES; FORECAST
  224.     7.2.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  225.     7.2.2 BY AGE GROUP, 2025-2035 (USD Billion)
  226.   7.3 US MARKET SIZE ESTIMATES; FORECAST
  227.     7.3.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  228.     7.3.2 BY AGE GROUP, 2025-2035 (USD Billion)
  229.   7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  230.     7.4.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  231.     7.4.2 BY AGE GROUP, 2025-2035 (USD Billion)
  232.   7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  233.     7.5.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  234.     7.5.2 BY AGE GROUP, 2025-2035 (USD Billion)
  235.   7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  236.     7.6.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  237.     7.6.2 BY AGE GROUP, 2025-2035 (USD Billion)
  238.   7.7 UK MARKET SIZE ESTIMATES; FORECAST
  239.     7.7.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  240.     7.7.2 BY AGE GROUP, 2025-2035 (USD Billion)
  241.   7.8 France MARKET SIZE ESTIMATES; FORECAST
  242.     7.8.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  243.     7.8.2 BY AGE GROUP, 2025-2035 (USD Billion)
  244.   7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  245.     7.9.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  246.     7.9.2 BY AGE GROUP, 2025-2035 (USD Billion)
  247.   7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  248.     7.10.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  249.     7.10.2 BY AGE GROUP, 2025-2035 (USD Billion)
  250.   7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  251.     7.11.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  252.     7.11.2 BY AGE GROUP, 2025-2035 (USD Billion)
  253.   7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  254.     7.12.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  255.     7.12.2 BY AGE GROUP, 2025-2035 (USD Billion)
  256.   7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  257.     7.13.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  258.     7.13.2 BY AGE GROUP, 2025-2035 (USD Billion)
  259.   7.14 China MARKET SIZE ESTIMATES; FORECAST
  260.     7.14.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  261.     7.14.2 BY AGE GROUP, 2025-2035 (USD Billion)
  262.   7.15 India MARKET SIZE ESTIMATES; FORECAST
  263.     7.15.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  264.     7.15.2 BY AGE GROUP, 2025-2035 (USD Billion)
  265.   7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  266.     7.16.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  267.     7.16.2 BY AGE GROUP, 2025-2035 (USD Billion)
  268.   7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  269.     7.17.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  270.     7.17.2 BY AGE GROUP, 2025-2035 (USD Billion)
  271.   7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  272.     7.18.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  273.     7.18.2 BY AGE GROUP, 2025-2035 (USD Billion)
  274.   7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  275.     7.19.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  276.     7.19.2 BY AGE GROUP, 2025-2035 (USD Billion)
  277.   7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  278.     7.20.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  279.     7.20.2 BY AGE GROUP, 2025-2035 (USD Billion)
  280.   7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  281.     7.21.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  282.     7.21.2 BY AGE GROUP, 2025-2035 (USD Billion)
  283.   7.22 South America MARKET SIZE ESTIMATES; FORECAST
  284.     7.22.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  285.     7.22.2 BY AGE GROUP, 2025-2035 (USD Billion)
  286.   7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  287.     7.23.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  288.     7.23.2 BY AGE GROUP, 2025-2035 (USD Billion)
  289.   7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  290.     7.24.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  291.     7.24.2 BY AGE GROUP, 2025-2035 (USD Billion)
  292.   7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  293.     7.25.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  294.     7.25.2 BY AGE GROUP, 2025-2035 (USD Billion)
  295.   7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  296.     7.26.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  297.     7.26.2 BY AGE GROUP, 2025-2035 (USD Billion)
  298.   7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  299.     7.27.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  300.     7.27.2 BY AGE GROUP, 2025-2035 (USD Billion)
  301.   7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  302.     7.28.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  303.     7.28.2 BY AGE GROUP, 2025-2035 (USD Billion)
  304.   7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  305.     7.29.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  306.     7.29.2 BY AGE GROUP, 2025-2035 (USD Billion)
  307.   7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  308.     7.30.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  309.     7.30.2 BY AGE GROUP, 2025-2035 (USD Billion)
  310.   7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  311.     7.31.1
  312.   7.32 ACQUISITION/PARTNERSHIP
  313.     7.32.1

Healthcare Market Segmentation

Healthcare By Treatment Type (USD Billion, 2025-2035)

  • Reverse Total Shoulder Replacement
  • Muscle/Tendon Transfer
  • Partial Joint Replacement
  • Others

Healthcare By Age Group (USD Billion, 2025-2035)

  • Less than 50
  • From 50 to 65
  • From 65 to 70

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions